Septerna, Inc. (SEPN) stock
SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30163% above fair value
$39.45−0.57 (-1.42%)
Close on Nov 18, 2026Market cap $1.84BP/E –Yield –
Septerna net income
Net income is the profit left for shareholders after every expense, interest and tax.
Septerna's net income for the twelve months ending Sep 30, 2026 was -$59.00M. For fiscal 2025 it was -$48.88M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.88M | – |
| FY2024 | Dec 31, 2024 | -$71.80M | -1817.7% |
| FY2023 | Dec 31, 2023 | $4.18M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.59M | -425.3% |
| Q2 FY2026 | Jun 30, 2026 | -$13.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.74M | – |
| Q3 FY2025 | Sep 30, 2025 | $8.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.67M | -159.2% |
| Q3 FY2024 | Sep 30, 2024 | -$20.52M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.10M | – |
| Q4 FY2023 | Dec 31, 2023 | $34.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.17M | – |
See a number that looks wrong?